摘要
目的 基于血清丝氨酸蛋白酶抑制剂(Vaspin)及Gensini积分变化探讨益心舒片联合曲美他嗪在冠心病心绞痛患者中的应用价值.方法 选取2020 年4 月—2021 年4 月就诊且接受益心舒片联合曲美他嗪治疗的冠心病心绞痛47 例作为联合组,同期收治接受曲美他嗪治疗的冠心病心绞痛47 例作为对照组.比较治疗前及治疗 3 个月后2 组心绞痛发作情况[发作频率、持续时间、视觉模拟评分法(VAS)评分]、中医证候积分(胸闷胸痛、心悸气短、失眠多梦、口唇发绀)、血液流变学指标(纤维蛋白原、血浆黏度、全血黏度)、血清炎性因子(C反应蛋白、白细胞介素-27、肿瘤坏死因子-α)、血清Vaspin、Gensini积分,以及治疗期间不良反应发生情况.结果 治疗3 个月后,2 组心绞痛发作频率、持续时间、VAS评分、中医证候积分、血液流变学指标、血清炎性因子及Gensini积分均低于或短于治疗前,且联合组VAS评分、中医证候积分、血清炎性因子及Gensini积分低于对照组;2 组血清Vaspin均高于治疗前,且联合组高于对照组(P＜0.05).治疗期间,联合组不良反应发生率 17.02%(8/47),对照组不良反应发生率 10.64%(5/47),2 组比较差异无统计学意义(P＞0.05).结论 益心舒片联合曲美他嗪治疗冠心病心绞痛患者效果显著,可减轻临床症状,降低血清炎性因子及Vaspin水平,调节血液流变状态,改善冠状动脉病变程度,且安全性好.
Abstract
Objective To investigate the application value of Yixinshu tablets combined with Trimetazidine in pa-tients with coronary heart disease(CHD)and angina pectoris based on the changes of serum serine protease inhibitor(Vaspin)level and Gensini score.Methods From April 2020 to April 2021,47 patients with CHD and angina pectoris who were treated with Yixinshu tablets combined with Trimetazidine were selected as the combination group,and 47 patients with CHD and angina pectoris treated with Trimetazidine during the same period were selected as the control group.The incidence of angina pectoris[frequency of attack,duration,visual analogue scale(VAS)score],TCM syndrome scores(chest tight-ness,chest pain,palpitation,shortness of breath,insomnia and dreaminess,cyanosis of the lips),hemorheological indexes[fibrinogen,plasma viscosity,whole blood viscosity],serum inflammatory factors[C-reactive protein(CRP),interleukin-27(IL-27),tumor necrosis factor α],serum Vaspin,Gensini scores,and the occurrence of adverse reactions during treatment were compared between the two groups before treatment and at 3 months after treatment.Results At 3 months after treat-ment,the frequency,duration,VAS score,TCM syndrome score,hemorheology index,serum inflammatory factor and Gensi-ni score of angina pectoris in the two groups were lower or shorter than those before treatment,and the VAS score,TCM syn-drome score,serum inflammatory factor and Gensini score of the combination group were lower than those of the control group.The serum Vaspin level in the two groups was higher than that before treatment,and higher in combination group than in con-trol group(P＜0.05).During treatment,the incidence of adverse reactions was 17.02%(8/47)in the combination group and 10.64%(5/47)in the control group,and there was no statistical significance between the two groups(P＞0.05).Con-clusion Yixinshu tablets combined with Trimetazidine is effective in the treatment of patients with CHD and angina pectoris,which can alleviate clinical symptoms,reduce serum inflammatory factors and Vaspin levels,regulate hemorheology,and im-prove the degree of coronary artery disease with good safety.
基金项目
河南省医学科技攻关计划项目(2018020860)
国家科技期刊平台
NSTL
万方数据